SGAM
RXII

Smith Group Asset Management’s GALENA BIOPHARMA INC COM RXII Stock Holding History

Smith Group Asset Management’s Portfolio RXII Stock Details RXII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-552,160
Closed -$1.14M – 461
2014
Q3 		$1.14M Sell
552,160
-1,920
-0.3% -$3.95K 0.04% 171
2014
Q2 		$1.7M Buy
+554,080
New +$1.7M 0.06% 164

Other funds holding RXII

BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Smith Group Asset Management's RXII Position: Q4 2014 in Review

Smith Group Asset Management sold out of GALENA BIOPHARMA INC COM (RXII) in Q4 2014, closing a stake of 552,160 shares — an estimated $1.14M sold.

Smith Group Asset Management first reported a position in RXII in Q2 2014 and held it in 2 quarters. The position peaked at $1.7M in Q2 2014. 79 funds tracked by Wall St. Rank hold RXII as of Q4 2014.

  • Smith Group Asset Management reported no remaining GALENA BIOPHARMA INC COM position as of Q4 2014 after selling out during the quarter.
  • Smith Group Asset Management sold 552,160 GALENA BIOPHARMA INC COM shares in Q4 2014, an estimated $1.14M.
  • Smith Group Asset Management first reported a position in GALENA BIOPHARMA INC COM in Q2 2014 and held it in 2 quarters.
  • Smith Group Asset Management's GALENA BIOPHARMA INC COM position peaked at $1.7M in Q2 2014.
  • 79 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q4 2014.

Based on Smith Group Asset Management's 13F filing for Q4 2014, filed 27 Jan 2015.